Last Posted: Nov 08, 2018
- Test Detects One in a Million Cancer Cells
R Voelker, JAMA, November 6, 2018
- Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh Trevor J et al. Cancer genetics 2018 Oct
- NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.
Yi Eun Sang et al. Cancer research and treatment : official journal of Korean Cancer Association 2018 Jul 50(3) 872-882
- The First Genome Surgeons- Scientists have built tools that can cheaply and easily edit DNA. Now they are preparing to bring them into the clinic to cure disease.
A Bleicher, the Medium, October 23, 2018
- Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.
Xu Xinjie et al. Cancer genetics 2018 Oct
- Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim Borahm et al. The Journal of molecular diagnostics : JMD 2018 Oct
- Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies.
Yang Shuanghui et al. Molecular therapy. Nucleic acids 2018 Sep 13164-175
- CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori Hasan et al. Human immunology 2018 Sep
- FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma,
FDA, September 28, 2018
- Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues.
Diouf Barthelemy et al. Clinical pharmacology and therapeutics 2018 Sep